
🚨 #ESMO26 Another promising ADC in 2L EGFRm NSCLC! Ph3 HER3 ADC ruzaltatug rezetecan vs chemo: 📈 PFS 8.3 vs 5.4m (HR 0.47) 📈 ORR 60% vs 34% 📈 OS HR 0.70 (immature) ⚠️ ILD 2.4% Competitive ADC landscape! More mature OS & global data needed.

Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18

🚨 #ESMO26 Another promising ADC in 2L EGFRm NSCLC! Ph3 HER3 ADC ruzaltatug rezetecan vs chemo: 📈 PFS 8.3 vs 5.4m (HR 0.47) 📈 ORR 60% vs 34% 📈 OS HR 0.70 (immature) ⚠️ ILD 2.4% Competitive ADC landscape! More mature OS & global data needed.

🚨 #ESMO26 Iza-bren 🇨🇳 Ph3 in EGFRm NSCLC post-TKI: 📈 PFS 11.1 vs 5.7m (HR 0.40) 📈 OS HR 0.66 (immature) ✅ ILD 0.9% A top contender among 2L ADCs? 🇬🇧 Excited to open global Ph3 IZABRIGHT-Lung01 at Barts in the next 2 weeks!

🚨 #ESMO26 Another Ph3 study reinforcing MET amp as a key target in EGFRm NSCLC! Dalmelitinib + aumolertinib vs chemo post-EGFR TKI: 📈 PFS 6.2 vs 4.4m (HR 0.60) 🔬 Reinforces importance of rebiopsy at progression, MET-amp accounts for ~10–15% (definition-dependent).

🚨 #ESMO26 SANOVO Ph3 🇨🇳 (China-only) Impressive 1L savolitinib + osimertinib in EGFRm/MET-OE NSCLC: 📈 PFS 24.9 vs 13.8m (HR 0.56) 📈 OS 44.5 vs 34.9m (HR 0.48) MET is a key target! ❓Target MET in 1L or 2L? Amivantimab already targets MET. Efficacy similar. Tox will be key


🚨 Practice-changing KRAS G12C NSCLC #ESMO26 Divarasib may be the most potent inhibitor yet 📈 PFS: 9.8 vs 5.7m (HR 0.58) 📈 OS: 17.7 vs 12.0m (HR 0.56) 🎯 ORR: 58% vs 32% Rapid 🇬🇧 reimbursement needed given challenges with sotorasib. 🔬 KRASCENDO-2 is OPEN at Barts!

🫁 #ESMO2026 OptiTROP-Lung04: Final OS analysis of sac-TMT vs chemotherapy in EGFRm NSCLC after EGFR-TKI progression. 🇨🇳 Chinese-only phase III (n=376) 📈 OS: 25.9 vs 17.4m (HR 0.69) Impressive OS benefit. Global data will be important 2nd line EGFR setting v. complex

🫁 #ESMO2026 OptiTROP-Lung06: sac-TMT + pembro vs chemo + pembro in PD-L1-negative NSCLC in china. High never smoker (30%) and male (60%) popn. Promising PFS: 15.0 vs 5.7m (HR 0.49). OS immature. Global data awaited Sac-TMT is also in clinical trials at @NHSBartsHealth

🫁 PERSEE phase III: Pembro + chemo vs pembro alone in PD-L1 ≥50% NSCLC. 📈 PFS: 16.1 vs 6.9m (HR 0.56) OS: HR 0.77 (95% CI 0.57–1.05) 29.9vs50 mo ⚠️ Grade ≥3 TRAEs: 54% vs 19% Better disease control, numerical better OS. Patient selection key - practice informing #ESMO2026

🇬🇧 UK-led SARON trial at #ESMO2026: 140 patients across 22 centres. Adding RT to systemic therapy in oligometastatic NSCLC improved PFS (13.9 vs 8.9 months) and local control, but not OS (HR 0.99). Important UK academic research informing clinical practice. #LungCancer #ESMO26

🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 nejm.org/doi/full/10.1056/NE…

🚨 PRACTICE-CHANGING in #SCLC! DeLLphi-305: tarlatamab + durvalumab maintenance ✅ 58% ↓ risk of death ✅ Median OS 21.1 vs 12.7 months ✅ 66% ↓ progression/death A huge advance for historically underserved patients with poor outcomes. 🇬🇧 Let’s expedite UK approval & NHS access

🇬🇧 Brilliant to see @tompowles1 AGAIN on the podium, leading the way in bladder cancer! 🚨 Phase III VOLGA: ✅ 49% ↓ EFS events/death ✅ 42% ↓ risk of death ✅ 45% pCR vs 10% Fantastic UK & @NHSBartsHealth representation! 👏 #BladderCancer #VOLGA #ESMO2026

🚨 Landmark Phase III cancer vaccine results! Personalised mRNA vaccine + pembrolizumab in melanoma: ⬇️ 42% risk of recurrence/death ⬇️ 38% risk of distant metastasis/death 🫁 Trials also recruiting in lung cancer, including early-stage disease at Barts! #ESMO26

🚨🔥‼️@OncoAlert Hot off the press. #BigNews #PressRelease by @Amgen ⭐️ #DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with Chemo + Durvalumab. Showed: ✅Statistically Significant & Clinically meaningful ⬆️#OverallSurvival (#OS) Benefit. 👇🏻 tinyurl.com/ytxbe2xf

#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: gene.com/media/press-release…